{
    "clinical_study": {
        "@rank": "52091", 
        "arm_group": [
            {
                "arm_group_label": "TAK-536CCB 20 mg/5 mg \uff0bPlacebo (dual therapy)", 
                "arm_group_type": "Active Comparator", 
                "description": "TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide (HCTZ) placebo for 10 weeks"
            }, 
            {
                "arm_group_label": "TAK-536CCB 20 mg/5 mg \uff0bHCTZ 6.25 mg (triple therapy)", 
                "arm_group_type": "Experimental", 
                "description": "TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide placebo (triple therapy) for the first 2 weeks of the treatment period and TAK-536CCB 20 mg/5 mg and HCTZ 6.25 mg for the remaining 8 weeks."
            }, 
            {
                "arm_group_label": "TAK-536CCB 20 mg/5 mg \uff0bHCTZ 12.5 mg (triple therapy)", 
                "arm_group_type": "Experimental", 
                "description": "TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide placebo for the first 2 weeks of the treatment period and TAK-536CCB 20 mg/5 mg and HCTZ 12.5 mg (triple therapy) for the remaining 8 weeks."
            }, 
            {
                "arm_group_label": "Placebo \uff0bHCTZ 6.25 mg (HCTZ monotherapy)", 
                "arm_group_type": "Active Comparator", 
                "description": "TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg (HCTZ monotherapy) for 10 weeks from the start of the treatment period."
            }, 
            {
                "arm_group_label": "Placebo \uff0bHydrochlorothiazide 12.5 mg (HCTZ monotherapy)", 
                "arm_group_type": "Active Comparator", 
                "description": "TAK-536CCB placebo and Hydrochlorothiazide 12.5 mg (HCTZ monotherapy) for 10 weeks from the start of the treatment period."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to compare the efficacy and safety of combined administration\n      of TAK-536CCB (Fix-dose combination of Azilsartan and Amlodipine) and Hydrochlorothiazide\n      (HCTZ) with those of TAK-536CCB in patients with Grade I or II essential hypertension."
        }, 
        "brief_title": "Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Grade I or II Essential Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "This study is a randomized, double-blind, multicenter, phase 2/3 study to evaluate the\n      efficacy and safety of combined administration of TAK-536CCB and Hydrochlorothiazide (HCTZ)\n      with those of TAK-536CCB or Hydrochlorothiazide in patients with grade I or II essential\n      hypertension.\n\n      This study consists of a 4-week single-blind placebo run-in period and a 10-week\n      double-blind treatment period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Grade I or II essential hypertension.\n\n          2. An office sitting systolic blood pressure of \u2265 150 and < 180 mmHg, and an office\n             sitting diastolic blood pressure of \u2265 95 and < 110 mmHg during the placebo run-in\n             period at Week \u22122 and Week 0.\n\n          3. Male or female aged 20 years or older at the time of providing informed consent.\n\n          4. Outpatient.\n\n        Exclusion Criteria:\n\n          1. Secondary hypertension, grade III hypertension or malignant hypertension.\n\n          2. An office sitting systolic blood pressure of \u2265160 mmHg or sitting diastolic blood\n             pressure of \u2265100 mmHg recorded while on combined therapy with 3 or more\n             antihypertensives within 4 weeks prior to the initiation of the placebo run-in period\n             and at Week \u22124.\n\n        3 Evident white coat hypertension or white coat phenomenon. 4. Day-night reversed\n        lifestyle, such as night-time workers. 5. Sleep apnea syndrome requiring treatment. 6.\n        Have any of the cardiovascular disease or symptoms listed below:\n\n          -  Heart disease: myocardial infarction (within 24 weeks before the placebo run-in\n             period), coronary arterial revascularization (within 24 weeks before the placebo\n             run-in period), severe valvular disease, atrial fibrillation, or following diseases\n             which require medication: angina pectoris, congested heart failure, or arrhythmia.\n\n          -  Cerebrovascular disease: cerebral infarction, cerebral hemorrhage (within 24 weeks\n             before the placebo run-in period), or transient ischemic attack (within 24 weeks\n             before the placebo run-in period).\n\n          -  Vascular diseases: peripheral arterial disease with intermittent claudication, artery\n             dissection, aneurysm\n\n          -  Advanced hypertensive retinopathy: bleeding, exudation, or papilledema (within 24\n             weeks before the placebo run-in period).\n\n             7. Clinically significant hepatic disorder. 8. Clinically significant renal\n             impairment. 9. Significantly low or high Potassium or Sodium levels. 10. Complicated\n             by gout, or had a past history of gout within 24 weeks prior to the initiation of the\n             placebo run-in period, or complicated by hyperuricemia requiring medication.\n\n             11. Diabetic subject on insulin treatment or poorly controlled type 2 diabetes\n             mellitus.\n\n             12. Have a malignant tumor."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "353", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02072330", 
            "org_study_id": "TAK-536TCH/CCT-001", 
            "secondary_id": "JapicCTI-121962"
        }, 
        "intervention": [
            {
                "arm_group_label": "TAK-536CCB 20 mg/5 mg \uff0bPlacebo (dual therapy)", 
                "description": "TAK-536CCB 20 mg/5 mg \uff0bHydrochlorothiazide placebo tablets", 
                "intervention_name": "TAK-536CCB", 
                "intervention_type": "Drug", 
                "other_name": "Fix-dose combination of Azilsartan and Amlodipine"
            }, 
            {
                "arm_group_label": "TAK-536CCB 20 mg/5 mg \uff0bHCTZ 6.25 mg (triple therapy)", 
                "description": "TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets", 
                "intervention_name": "TAK-536CCB + Hydrochlorothiazide", 
                "intervention_type": "Drug", 
                "other_name": "Hydrochlorothiazide and fix-dose combination of Azilsartan and Amlodipine"
            }, 
            {
                "arm_group_label": "Placebo \uff0bHCTZ 6.25 mg (HCTZ monotherapy)", 
                "description": "TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets", 
                "intervention_name": "Hydrochlorothiazide", 
                "intervention_type": "Drug", 
                "other_name": "Hydrochlorothiazide"
            }, 
            {
                "arm_group_label": "Placebo \uff0bHydrochlorothiazide 12.5 mg (HCTZ monotherapy)", 
                "description": "TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets x2", 
                "intervention_name": "Hydrochlorothiazide", 
                "intervention_type": "Drug", 
                "other_name": "Hydrochlorothiazide"
            }, 
            {
                "arm_group_label": "TAK-536CCB 20 mg/5 mg \uff0bHCTZ 12.5 mg (triple therapy)", 
                "description": "TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets x2", 
                "intervention_name": "TAK-536CCB + Hydrochlorothiazide", 
                "intervention_type": "Drug", 
                "other_name": "Hydrochlorothiazide and fix-dose combination of Azilsartan and Amlodipine"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hydrochlorothiazide", 
                "Amlodipine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Hypertension, Drug therapy", 
        "lastchanged_date": "February 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Touon-shi", 
                        "country": "Japan", 
                        "state": "Ehime"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka-shi", 
                        "country": "Japan", 
                        "state": "Fukuoka"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hiroshima-shi", 
                        "country": "Japan", 
                        "state": "Hiroshima"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo-shi", 
                        "country": "Japan", 
                        "state": "Hokkaido"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hanamaki-shi", 
                        "country": "Japan", 
                        "state": "Iwate"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morioka-shi", 
                        "country": "Japan", 
                        "state": "Iwate"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kumamoto-shi", 
                        "country": "Japan", 
                        "state": "Kumamoto"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyoto-shi", 
                        "country": "Japan", 
                        "state": "Kyoto"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sendai-shi", 
                        "country": "Japan", 
                        "state": "Miyagi"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka-shi", 
                        "country": "Japan", 
                        "state": "Osaka"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suita-shi", 
                        "country": "Japan", 
                        "state": "Osaka"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shinjuku-ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toyama-shi", 
                        "country": "Japan", 
                        "state": "Toyama"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Randomized, Double-Blind, Multicenter, Phase 2/3 Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB (Fix-dose Combination of Azilsartan and Amlodipine) and Hydrochlorothiazide in Comparison With TAK-536CCB or Hydrochlorothiazide Monotherapy in Patients With Grade I or II Essential Hypertension", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Senior Manager", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Change in the office trough sitting DBP from the end of the placebo run-in period (baseline [Week 0]) to the end of the treatment period (Week 10, last observation carried forward [LOCF])", 
            "measure": "Change from Baseline in the office trough sitting diastolic blood pressure (DBP)", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 10"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02072330"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in the office trough sitting SBP from the end of the placebo run-in period (baseline [Week 0]) to the end of the treatment period (Week 10, last observation carried forward [LOCF])", 
                "measure": "Change from Baseline in the office trough sitting systolic blood pressure (SBP)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 10"
            }, 
            {
                "description": "Patients achieving < 140/90 mmHg  refer to those meeting both of the following criteria:\nA decrease to  < 90 mmHg in office trough sitting DBP\nA decrease to  < 140 mmHg in office trough sitting SBP", 
                "measure": "Proportion of patients achieving < 140/90 mmHg", 
                "safety_issue": "No", 
                "time_frame": "10 weeks"
            }, 
            {
                "description": "Patients who met either of the following conditions are regarded as responders (140/90 mmHg criterion).\nA \u2265 20 mmHg decrease in office trough sitting SBP and a \u2265 10 mmHg decrease in the office trough sitting DBP\nA decrease to < 140 mmHg in office trough sitting SBP and a decrease to < 90 mmHg in office trough sitting DBP", 
                "measure": "Proportion of responders (140/90 mmHg criterion)", 
                "safety_issue": "No", 
                "time_frame": "10 weeks"
            }, 
            {
                "description": "The frequency of adverse events by type, seriousness. Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug to the last dose of study drug", 
                "measure": "Frequency of adverse events( including vital sign, body weight, ECG findings and laboratory tests)", 
                "safety_issue": "Yes", 
                "time_frame": "10 weeks"
            }, 
            {
                "measure": "Time profile of office trough sitting diastolic blood pressure", 
                "safety_issue": "No", 
                "time_frame": "10 weeks"
            }, 
            {
                "measure": "Time profile of office trough sitting systolic blood pressure", 
                "safety_issue": "No", 
                "time_frame": "10 weeks"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}